

Chapter 170

Raynaud Phenomenon

John H. Klippel

REFERENCES

1. Brand FN et al: The occurrence of Raynaud's phenomenon in a general population: The Framingham Study. *Vasc Med* 2:296, 1997 [PMID: 9575602]
2. Gelber AC et al: Symptoms of Raynaud's phenomenon in an inner-city African-American community: Prevalence and self-reported cardiovascular comorbidity. *J Clin Epidemiol* 52:441, 1999 [PMID: 10360339]
3. Hirschl M, Kundi M: Initial prevalence and incidence of secondary Raynaud's phenomenon in patients with Raynaud's symptomatology. *J Rheumatol* 23:302, 1996 [PMID: 8882036]
4. Greenstein D et al: The menstrual cycle and Raynaud's phenomenon. *Angiology* 47:427, 1996 [PMID: 8644939]
5. Gardner-Medwin JM et al: Seasonal differences in finger skin temperature and microvascular blood flow in healthy men and women are exaggerated in women with primary Raynaud's phenomenon. *Br J Clin Pharmacol* 52:17, 2001 [PMID: 11453886]
6. Fraenkel L et al: Different factors influencing the expression of Raynaud's phenomenon in men and women. *Arthritis Rheum* 42:306, 1999 [PMID: 10025925]
7. Freedman RR, Mayes MD: Familial aggregation of primary Raynaud's disease. *Arthritis Rheum* 39:1189, 1996 [PMID: 8670329]
8. Maricq HR et al: Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders. *J Rheumatol* 23:2068, 1996 [PMID: 8970043]
9. Herrick AL et al: von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. *Ann Rheum Dis* 55:122, 1996 [PMID: 8712862]
10. Koenig M et al: Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients with validation of proposed criteria for early systemic sclerosis. *Arthritis Rheum* 58:3902, 2008
11. Toms SL, Cooke ED: A comparison of the functioning of arteriovenous anastomoses in secondary Raynaud's phenomenon and control subjects in response to local hand warming. *Int Angiol* 14:74, 1995
12. Chen GS et al: Responses of cutaneous microcirculation to cold exposure and neuropathy in vibration-induced white finger. *Microvasc Res* 47:21, 1994 [PMID: 8022312]
13. Susol E et al: A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. *Arthritis Rheum* 43:1641, 2000 [PMID: 10902770]
14. Anders HJ et al: Differentiation between primary and secondary Raynaud's phenomenon: A prospective study comparing nail fold capillaroscopy using an ophthalmoscope or stereomicroscope. *Ann Rheum Dis* 60:407, 2001
15. Ohtsuka T: Quantitative analysis of nail fold capillary abnormalities in patients with connective tissue diseases. *Int J Dermatol* 38:757, 1999 [PMID: 10561047]
16. ter Borg EJ et al: Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. *Semin Arthritis Rheum* 24:40, 1994
17. Murray AK et al: Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. *Arthritis Rheum* 61:1103, 2009
18. Rosato E et al: Laser Doppler perfusion imaging is useful in the study of Raynaud's phenomenon and improves capillaroscopic diagnosis. *J Rheumatol* 36:2257, 2009
19. Allen EV, Brown GE: Raynaud's disease: A critical review of minimal prerequisites for diagnosis. *Am J Med Sci* 183:187, 1932
20. LeRoy EC, Medsger TA Jr: Raynaud's phenomenon: A proposal for classification. *Clin Exp Rheumatol* 10:485, 1992 [PMID: 1458701]
21. Spencer-Green G: Outcome in primary Raynaud phenomenon: A meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. *Arch Intern Med* 158:595, 1998
22. Hirschi M et al: Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease. *Arthritis Rheum* 54:1974, 2006

23. Palmer KT et al: Prevalence of Raynaud's phenomenon in Great Britain and its relation to hand transmitted vibration: A national postal survey. *Occup Environ Med* **57**:448, 2000 [PMID: 10854496]
24. Herrick AL et al: Abnormal thermoregulatory responses in patients with reflex sympathetic dystrophy syndrome. *J Rheumatol* **21**:1319, 1994
25. Doll DC, Yarbrow JW: Vascular toxicity associated with chemotherapy and hormonotherapy. *Curr Opin Oncol* **6**:345, 1994 [PMID: 7803535]
26. Thompson AE et al: Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. *Arthritis Rheum* **44**:1841, 2001
27. Thompson AE, Pope JE: Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. *Rheumatology* **44**:145, 2005 [PMID: 15546967]
28. Coleiro B et al: Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. *Rheumatology* **40**:1038, 2001
29. Denton CP et al: Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A pilot study. *Clin Exp Rheumatol* **18**:499, 2000
30. Pope J et al: Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. *Cochrane Database Syst Rev* (2):CD000956, 2000
31. Dziadzio M et al: Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. *Arthritis Rheum* **42**:2646, 1999 [PMID: 10616013]
32. Helfman T, Falanga V: Stanazolol as a novel therapeutic agent in dermatology. *J Am Acad Dermatol* **33**:254, 1995 [PMID: 7622653]
33. Teh LS et al: Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. *Br J Rheumatol* **34**:636, 1995 [PMID: 7670782]
34. Chung L et al: MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. *Arthritis Rheum* **60**:870, 2009
35. Pope J et al: Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. *Cochrane Database Syst Rev* (2):CD000953, 2000
36. Scorza R et al: Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. *Clin Exp Rheumatol* **19**:503, 2001 [PMID: 11579708]
37. Gardinella M et al: Treatment of Raynaud's phenomenon with intravenous prostaglandin E1 alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. *J Rheumatol* **28**:786, 2001
38. Bettoni L et al: Systemic sclerosis therapy with iloprost: A prospective observational study of 30 patients treated for a median of 3 years. *Clin Rheumatol* **21**:244, 2002 [PMID: 12111631]
39. Hartzell TL et al: Long-term results of periarterial sympathectomy. *J Hand Surg Am* **34**:1454, 2009
40. Tomaino MM et al: Surgery for ischemic pain and Raynaud's phenomenon in scleroderma: A description of treatment protocol and evaluation of results. *Microsurgery* **21**:75, 2001 [PMID: 11372066]